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Surfactant protein D (SP-D) is a pattern recognition molecule belonging to the Collectin 
(collagen-containing C-type lectin) family that has pulmonary as well as extra-pulmonary 
existence. In the lungs, it is a well-established opsonin that can agglutinate a range of 
microbes, and enhance their clearance via phagocytosis and super-oxidative burst. It 
can interfere with allergen–IgE interaction and suppress basophil and mast cell activa-
tion. However, it is now becoming evident that SP-D is likely to be an innate immune 
surveillance molecule against tumor development. SP-D has been shown to induce 
apoptosis in sensitized eosinophils derived from allergic patients and a leukemic cell line 
via p53 pathway. Recently, SP-D has been shown to suppress lung cancer progression 
via interference with the epidermal growth factor signaling. In addition, a truncated 
form of recombinant human SP-D has been reported to induce apoptosis in pancreatic 
adenocarcinoma via Fas-mediated pathway in a p53-independent manner. To further 
establish a correlation between SP-D presence/levels and normal and cancer tissues, 
we performed a bioinformatics analysis, using Oncomine dataset and the survival analy-
sis platforms Kaplan–Meier plotter, to assess if SP-D can serve as a potential prognostic 
marker for human lung cancer, in addition to human gastric, breast, and ovarian cancers. 
We also analyzed immunohistochemically the presence of SP-D in normal and tumor 
human tissues. We conclude that (1) in the lung, gastric, and breast cancers, there is 
a lower expression of SP-D than normal tissues; (2) in ovarian cancer, there is a higher 
expression of SP-D than normal tissue; and (3) in lung cancer, the presence of SP-D 
could be associated with a favorable prognosis. On the contrary, at non-pulmonary sites 
such as gastric, breast, and ovarian cancers, the presence of SP-D could be associated 
with unfavorable prognosis. Correlation between the levels of SP-D and overall survival 
requires further investigation. Our analysis involves a large number of dataset; therefore, 
any trend observed is reliable. Despite apparent complexity within the results, it is evident 
that cancer tissues that produce less levels of SP-D compared to their normal tissue 
counterparts are probably less susceptible to SP-D-mediated immune surveillance 
mechanisms via infiltrating immune cells.
Keywords: innate immunity, surfactant protein D, immune surveillance, bioinformatics analysis, immuno­
histochemistry, cancers, tumor microenvironment
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inTrODUcTiOn
Surfactant protein D (SP-D) is a collagenous glycoprotein 
encoded by SFTPD gene belonging to the collectins family 
(1). Like other members of the collectin family, SP-D has a 
primary subunit structure that comprises of an N-terminal 
cysteine-rich region, a triple-helical collagen-like domain, 
an α-helical coiled neck domain, and a C-terminal C-type 
lectin domain [also called carbohydrate recognition domain 
(CRD)] (2). Each subunit of human SP-D comprises three 
identical polypeptide chains of 43  kDa, which is assembled 
into a tetrameric structure with four of the homotrimeric 
subunits linked via their N-terminal regions, but trimers, 
dimers, and monomers also exist. Tetrameric structures can 
undergo further oligomerization to give SP-D multimers that 
could contain up to 96 individual chains. SP-D was originally 
described in association with pulmonary surfactant; in the 
lung, it is synthesized and secreted by type II alveolar cells and 
non-ciliated bronchiolar epithelial cells. It has a key role in the 
maintenance of surfactant homeostasis by reducing surface 
tension (3). Reduced SP-D expression or genetic variations 
(single-nucleotide polymorphism) have been associated with 
an increased risk of respiratory diseases (4, 5).
Extra-pulmonary existence of SP-D has also been reported. 
SP-D is also expressed by epithelial cells lining various exocrine 
ducts, the mucosa of the gastrointestinal and genitourinary tracts, 
the nasal cavity, and in the brain (2). Furthermore, its presence 
has been demonstrated in healthy lacrimal gland, conjunctiva, 
cornea, and nasolacrimal duct samples (6). Other studies have 
shown the presence of SP-D in synovial fluid derived from 
patients with rheumatoid arthritis (7).
In addition to its role in surfactant homeostasis, SP-D has a 
critical function as a regulator of inflammation (3). It is involved 
in the recognition and neutralization of pathogens which promotes 
aggregation/agglutination and inhibition of microbial growth (8), 
SP-D has also been implicated in the clearance of necrotic and 
apoptotic cells (9). Thus, its function in the recognition of non-self 
and altered self makes it a potent and versatile humoral pattern 
recognition receptor (10–12). SP-D has also been described as a 
potent link between innate and adaptive immune mechanisms 
(13–15). Studies involving in vivo and ex vivo models of allergic 
inflammation revealed that SP-D can alleviate pulmonary hyper-
sensitivity via suppression of IgE levels, promotion of Th2 to Th1 
polarization (16), apoptosis induction in sensitized eosinophils 
via p53-mediated pathway (17), and inhibition of IgE synthesis 
by B cells (18). These studies highlighted a potential role of SP-D 
as an immune surveillance molecule. It has recently been shown 
that SP-D also plays a role in the control of lung cancer progres-
sion via epidermal growth factor (EGF) signaling (19). Very 
recently, Kaur et al. have shown that a recombinant fragment of 
human SP-D, composed of homotrimeric neck and C-type lectin 
domains, can induce apoptosis in pancreatic adenocarcinoma cell 
lines, such as Panc-1 (p53mt), MiaPaCa-2 (p53mt), and Capan-2 
(p53wt), via Fas-mediated pathway (20).
In the current study, we performed a bioinformatics analysis 
in order to investigate whether SP-D can serve as a potential 
prognostic marker for human lung cancer. We extended our 
investigation to several non-pulmonary sites such as human gas-
tric, breast, and ovarian cancer. We used the Oncomine dataset 
and the survival analysis platforms Kaplan–Meier plotter. Our 
results appear to suggest a likely pro-tumorigenic role of SP-D 
in gastric, breast, and ovarian cancers and an anti-tumor effect in 
lung cancer. Furthermore, we analyzed the presence of SP-D in 
normal and tumor human tissues via immunohistochemistry 
(IHC). Differential expression of SP-D was also investigated in 
human cells isolated from normal and tumor ovary tissues by 
real-time PCR. This in silico study, if validated via a retrospective 
study at the protein level, could be a step forward in ascertaining 
the importance of SP-D as a prognostic biomarker for different 
cancers.
MaTerials anD MeThODs
Oncomine Database analysis
The expression level of SFTPD gene in various types of cancer 
was analyzed using Oncomine,1 a cancer microarray database and 
web-based data mining platform from genome-wide expression 
analyses (21, 22). We compared the differences in mRNA level 
between normal tissue and cancer. The mRNA expression level 
in neoplastic tissues compared to the healthy tissues was obtained 
as the parameters of p-value < 0.001, fold change > all, and gene 
ranking in the top 10%. Information about the datasets used in 
this study is summarized in Table 1.
Kaplan–Meier Plotter Database analysis
A Kaplan–Meier plotter database can assess the effect of 54,675 
genes on survival using 10,461 cancer samples (5,143 breast, 
1,816 ovarian, 2,437 lung, and 1,065 gastric cancer patients with 
a mean follow-up of 69/40/49/33  months) using probe sets on 
the HGU133 Plus 2.0 array. The prognostic significance of SP-D 
expression and survival in breast, ovarian, lung, and gastric 
cancer was analyzed by Kaplan–Meier plotter2 (23). The hazard 
ratio with 95% confidence intervals and logrank p-value was also 
computed.
Patients and specimens
Eight fresh clinical specimens (four normal ovarian epithelial 
tissues and four malignant ovarian epithelial tumor tissues) 
were obtained from the Department of Gynaecology of IRCCS 
“Burlo Garofolo”, in Trieste, Italy between 2016 and 2017. 
Cancer patients underwent laparoscopy for diagnosis of pelvic 
mass whereas control patients underwent laparoscopy for other 
indications. Tissue samples from patients were collected after 
informed consent following ethical approval by the Institutional 
Board of IRCCS “Burlo Garofolo”, Trieste, Italy.
immunohistochemical analysis
For the immunohistochemical analysis, human normal and 
neoplastic tissues, including lung, breast, ovary, and stomach 
samples, were selected from the archives of the Department of 
1 www.oncomine.org.
2 www.kmplot.com.
Table 1 | Data characteristics used in the bioinformatics analysis.
Datasets study description experiment type
Bhattacharjee lung 139 lung adenocarcinoma, 21 squamous cell lung carcinoma, 20 lung carcinoid tumor, 6 small cell lung carcinoma, and 17 
normal lung samples were analyzed on Affymetrix U95A microarrays. Sample data includes type, age, M stage, max tumor 
percentage, N stage, primary/metastatic, recurrence, sex, site of metastasis, smoking rate (packs per year), stage, survival, 
and T stage
mRNA
Hou lung 91 non-small cell lung carcinoma and 65 adjacent normal lung samples were analyzed. Sample data includes age, sex, cancer 
sample site, and survival
mRNA
Garber lung 67 lung carcinoma samples of various types and 6 normal lung samples were analyzed on cDNA microarrays. Sample data 
includes type, grade, TNM stage, and survival
mRNA
Cho gastric 65 gastric adenocarcinoma, 19 paired surrounding normal tissue, and 6 gastrointestinal stromal tumor samples were analyzed. 
Sample data includes age, grade, stage, TNM stage, sex, and subgroup
mRNA
DErrico gastric 31 paired gastric carcinoma and adjacent normal gastric mucosa and 7 unmatched gastric carcinoma samples were analyzed. 
Sample data includes microsatellite status, age, sex, and TNM stage
mRNA
Zhao breast Normal breast (n = 3) and breast carcinoma (n = 61) samples were analyzed on cDNA microarrays. Sample data includes 
tumor percentage, age, E-Cadherin status, estrogen receptor status, grade, HER2 status, lymph node metastasis status, and 
progesterone receptor status
mRNA
TCGA breast 532 invasive breast carcinoma, 61 paired normal breast tissue, and 3 paired metastatic samples were analyzed. Sample data 
includes age, histology, TNM stage, ER/PR/ERBB2 status, sex, stage, and others. This dataset consists of Level 2 (processed) 
data from the TCGA data portal
mRNA
Curtis breast 1,992 breast carcinoma samples and 144 paired normal breast samples were analyzed for the METABRIC project. Sample 
data includes ER/PR/ERBB2 status, overall survival status and follow-up time, stage, grade, and others
mRNA
Yoshihara ovarian 43 ovarian serous adenocarcinomas and 10 normal peritoneum samples were analyzed. Sample data includes cancer sample 
site, stage, and sex
mRNA
TCGA ovarian 586 ovarian serous cystadenocarcinoma samples and 8 normal ovary samples were analyzed. Sample data includes age, 
stage, grade, survival, and others. This dataset consists of Level 2 (processed) data from the TCGA data portal
mRNA
Abbreviations: TNM, Tumor-Nodes-Metastasis; HER2,  Human Epidermal Growth Factor Receptor 2; ER, Estrogen Receptor; PR, Progesterone Receptor; ERBB, Erb-b2 receptor 
tyrosine kinase 2.
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Pathology, University of Palermo. Immunohistochemistry (IHC) 
was performed using a polymer detection method. Briefly, tissue 
samples were fixed in 10% v/v buffered formalin and then paraf-
fin embedded. 4 µm-thick tissue sections were deparaffinized and 
rehydrated. The antigen unmasking technique was carried out using 
Novocastra Epitope Retrieval Solutions, pH 9 (Leica Biosystems) 
in a PT Link pre-treatment module (Dako) at 98°C for 30 min. 
Sections were then brought to room temperature and washed in 
PBS. After neutralization of the endogenous peroxidase with 3% 
v/v H2O2 and Fc blocking by a specific protein block (Novocastra, 
Leica Biosystems), samples were incubated overnight at 4°C with 
rabbit anti-human SP-D (dilution 1:300) polyclonal antibod-
ies (MRC Immunochemistry Unit, Oxford, UK). Staining was 
revealed via polymer detection kit (Novocastra, Leica Biosystems) 
and AEC (3-amino-9-ethylcarbazole, Dako, Denmark) substrate-
chromogen. Slides were counterstained with Harris Hematoxylin 
(Novocastra, Leica Biosystems). Sections were analyzed under the 
Axio Scope A1 optical microscope (Zeiss) and microphotographs 
were collected through the Axiocam 503 color digital camera 
(Zeiss) using the Zen2 software.
cell isolation and culture
Ovarian carcinoma cells (OvCa) and normal epithelial ovarian 
cells (OvEp) were isolated from biopsies derived from ovarian 
tissue. The tissue was finely minced with a cutter, incubated with 
a digestion solution composed by 0.5% trypsin (Sigma-Aldrich, 
Milan, Italy) and 50  µg/ml DNase I (Roche, Milan, Italy) in 
Hanks’ Balanced Salt solution containing 0.5  mM Ca2+Mg2+ 
(Sigma-Aldrich) overnight at 4°C. Next, the enzymatic solution 
was changed to collagenase type 1 (1.5  mg/ml) (Worthington 
Biochemical Corporation, DBA) diluted in Medium 199 with 
Hank’s salts (Euroclone Spa, Milan, Italy) for 30  min at 37°C. 
The digestion was blocked with 10% v/v fetal bovine serum (FBS; 
GIBCO, Life Technology) and the cell suspension was passed 
through a 100 µm pore filter (BD Biosciences, Italy). The cells were 
seeded in a 25 cm2 flask, coated with bovine gelatine, and cultured 
using Human Endothelial cells serum-free medium (HESF; Life 
Technologies), 10% heat-inactivated FBS supplemented with EGF 
(10 ng/ml), basic FGF (20 ng/ml) and Penicillin–Streptomycin 
(Sigma-Aldrich). Fresh medium was replaced every 2–3  days. 
The cells were maintained at 37°C in humidified atmosphere with 
5% v/v CO2 and used at their fifth to eighth passage for in vitro 
experiments.
rna isolation, cDna synthesis, and 
Quantitative real­Time Pcr (qPcr)
Total RNA was extracted from cells using EuroGOLD trifast 
(Euroclone), according to the manufacturer’s instructions, 
and reverse-transcribed as previously described (24). qPCR 
was carried out using a Rotor-Gene 6000 (Corbett, Qiangen, 
Ancona, Italy) using iQ SYBR Green Supermix (Applied 
Biosystems, Milan, Italy). The sequences of the primers used for 
amplification of TataBox Binding Protein (TBP) housekeeping 
gene are Forward 5′-GAGCCAAGAGTGAAGAACAGTC-3′; 
Reverse 5′-GCTCCCCACCATATTCTGAATCT-3′. The 
sequences of SP-D primers are Forward 5′-AGGCTGCTTTC 
FigUre 1 | Pathological significance of SP-D expression in lung cancer. Bhattacharjee’s and Hou’s datasets were used for bioinformatics analysis to explore SP-D 
mRNA expression in the lung cancer. A lower SP-D mRNA expression was detectable in lung adenocarcinoma, squamous cell carcinoma, large cell carcinoma, 
small cell carcinoma, and tumor carcinoid than in normal lung tissue [(a) p < 0.05]. According to the data from Kaplan–Meir plotter, SP-D mRNA expression was 
positively related to an overall survival rate of the patients with lung cancer, even stratified into lung adenocarcinoma and squamous cell carcinoma [(b) p < 0.05]. 
Abbreviations: HR, hazard ratio; SP-D, surfactant protein D.
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CTGAGCATGAC-3′; Reverse 5′-CCATTGGTGAAGATCTCC 
ACACAG-3′. The melting curve was recorded between 55 and 
99°C with a hold every 2 s. The relative amount of gene production 
in each sample was determined by the Comparative Quantification 
method supplied as part of the Rotor Gene 1.7 software (Corbett 
Research) (25). The relative amount of each gene was normalized 
with TBP and expressed as arbitrary units (AU) considering 1 AU 
obtained from fully differentiated macrophage used as calibrator.
statistical analysis
Survival curves were generated by the Kaplan–Meier plots. 
All results are displayed with p values from a logrank test. p- 
values < 0.05 were considered significant. Similarly, with Oncomine, 
the statistical significance of data (p-values) was provided by the 
program.
resUlTs
clinical significance of sP­D expression in 
lung cancer
We initially compared the differences in the mRNA level of SP-D 
between neoplastic and healthy tissues using the Oncomine 
platform. While analyzing Bhattacharjee’s, Hou’s, and Garber’s 
datasets, we detected a significantly lower SP-D mRNA expres-
sion in lung adenocarcinoma, squamous cell carcinoma, large cell 
carcinoma, small cell carcinoma, and tumor carcinoid, compared 
to the normal lung tissue (Figure  1A, p <  0.05; Figure S1 in 
Supplementary Material, p < 0.05). We subsequently performed 
a bioinformatic analysis of SP-D mRNA expression using the 
Kaplan–Meier plotter dataset. As shown in Figure  1B, SP-D 
mRNA expression was positively related to an overall survival 
rate of the patients with lung cancer, stratified into lung adeno-
carcinoma and squamous cell carcinoma (p < 0.05).
IHC staining for SP-D confirmed a differential expression in 
healthy and neoplastic pulmonary parenchyma. Moreover, in 
lung adenocarcinoma and squamous cell lung carcinoma tissues, 
we observed a lower expression of SP-D within its microenviron-
ment compared to the healthy pulmonary parenchyma (Figure 2).
Pathological significance of sP­D mrna 
expression in gastric, breast, and Ovarian 
cancers
The bioinformatics analysis on SP-D mRNA expression in 
gastric cancer via Cho’s and DErrico’s datasets showed its higher 
expression in healthy gastric mucosa compared to its malignant 
counterpart, stratified into intestinal, diffuse, and mixed-type 
FigUre 2 | Immunohistochemistry analysis for surfactant protein D (SP-D) in lung. Compared to healthy lung (a,b) a decreased expression of SP-D in 
adenocarcinoma (c) and squamous cell carcinoma of the lung (D) was observed. Polymer detection system with AEC (red) chromogen was used; scale bars, 
50 μm. Polymer detection system with AEC (red) chromogen was used; scale bars, 50 µm.
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adenocarcinoma by Lauren’s classification (Figure 3A, p < 0.05; 
Figure S2 in Supplementary Material, p < 0.05). According to the 
data from Kaplan–Meier plotter, SP-D mRNA expression was 
negatively related to an overall survival rate of the patients with 
gastric cancer (Figure 3B, p < 0.05). If stratified by Lauren’s clas-
sification, SP-D mRNA expression had a statistically significant 
association with intestinal-type adenocarcinoma, whereas no 
association with diffuse- and mixed-type adenocarcinomas was 
found (Figure 3C, p < 0.05). A higher expression of SP-D was 
negatively correlated with an overall survival rate in the patients 
without distant metastasis, HER2-negative and only intestinal-
type adenocarcinoma (Figure 3D, p < 0.05).
The information regarding the SP-D mRNA expression in 
breast cancer was obtained from Zhao’s, TCGA’s, and Curtis’s 
datasets, which showed that SFTPD was expressed at a lower 
level in invasive ductal breast carcinoma, male breast carcinoma, 
and breast phyllodes tumor, compared to normal breast tissues 
(Figure  4A, p <  0.05; Figure S3A in Supplementary Material, 
p < 0.05). According to the data from Kaplan–Meir plotter, SFTPD 
expression was negatively linked to the high overall survival rate 
in breast cancer patients with Luminal-A grade-1 and grade-2 
cancers (Figure  4B, p  <  0.05; Figure S3B in Supplementary 
Material, p < 0.05). No correlation between SP-D mRNA expres-
sion and overall survival rate was observed in patients with the 
other characteristics (Luminal-B, HER2+, Basal, grade-3, mutated 
p53, wild-type p53).
Using IHC, we observed a variable presence and distribution of 
SP-D in normal tissues with respect to their cancer counterpart. 
In fact, IHC performed on either healthy or neoplastic gastric 
mucosa highlighted a significantly reduced expression of SP-D in 
the intestinal-type adenocarcinoma compared to gastric control 
tissue (Figures  5A,C). Likewise, a higher expression of SP-D 
in the normal mammary parenchyma was detected compared 
to that observed within microenvironment within the invasive 
ductal breast carcinoma, Luminal-A (Figures 5B,D).
We collected the results from Yoshihara’s and TCGA’s datasets 
and analyzed SFTPD expression in ovarian cancer. We observed 
a lower expression of SFTPD mRNA expression in normal ovary 
than in serous cystadenocarcinoma (Figure 6A, p < 0.05). The 
Kaplan–Meier plotter data, derived from stage-1 and -2 patients, 
showed a negative ratio between SFTPD expression and either 
overall or progression-free survival rates of patients with serous 
cystadenocarcinoma (Figure  6B, p <  0.05). However, no cor-
relation was observed between SFTPD expression and these 
parameters (overall or progression-free survival rates) of patients 
with stage-3 and -4 ovarian cancer.
sP­D expression in the Microenvironment 
of Ovarian cancer
The mRNA expression of SP-D was also evaluated by real-time 
PCR in primary cells isolated from four samples each of human 
ovarian serous cystadenocarcinoma and normal ovarian tissues. 
As shown in Figure  7A, the cells isolated from ovarian serous 
cystoadenocarcinoma tissues expressed more SP-D compared to 
the normal tissue, confirming the data obtained with the bioinfor-
matics analysis. IHC analysis also revealed the presence and the 
distribution of SP-D in the normal ovary where it appeared to be 
localized in the ovarian epithelium lining and in the serous cystad-
enocarcinoma. In addition, we detected a differential expression 
FigUre 3 | Pathological significance of SP-D expression in gastric cancer. Cho’s dataset has explored SP-D mRNA expression in gastric cancer. A lower SFTPD 
expression was detectable in gastric cancer than that in normal mucosa, even stratified into diffuse-, intestinal-, and mixed-type adenocarcinomas by Lauren’s 
classification [(a) p < 0.05]. According to the data from Kaplan–Meier plotter, SP-D mRNA expression was negatively related to an overall survival rate of the patients 
with gastric cancer [(b) p < 0.05]. If stratified by Lauren’s classification, SP-D mRNA expression was negatively related to an overall survival rate in the patients with 
intestinal-type adenocarcinoma [(c) p < 0.05], without distant metastasis and Her2-negative [(D) p < 0.05]. Abbreviations: HR, hazard ratio; SP-D, surfactant protein D.
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in the normal as well as its malignant histotypes. Moreover, in the 
ovarian context, it showed an enrichment of SP-D expressing cells 
within the tumor microenvironment compared to the control 
tissue (Figures 7B,C).
DiscUssiOn
The importance of SP-D in the regulation of the inflammation and 
homeostasis and in the protection against infection and allergens 
in the lung and at a range of extra-pulmonary mucosal sites is 
well documented (26, 27). However, there are recent evidences 
to implicate SP-D as an immune surveillance molecule against 
cancer (19, 20). In this study, we examined the potential prog-
nostic value of this protein in lung, gastric, breast, and ovarian 
cancers. We focused our attention on these tumor types because 
we performed a bioinformatics analysis using the Kaplan–Meier 
plotter dataset, a manually curated database containing the infor-
mation of 54,675 genes on 5,143 breast, 1,816 ovarian, 2,437 lung, 
and 1,065 gastric cancer samples. This is the most updated and 
reliable dataset available that offers the possibility of stratifying 
FigUre 4 | The clinicopathological significances of SP-D expression in breast cancer. Zhao’s and TCGA’s datasets have revealed a lower SP-D mRNA expression 
in invasive ductal breast carcinoma and male breast carcinoma than in normal breast tissues [(a) p < 0.05]. There was a negative association between SP-D mRNA 
expression and a favorable prognosis in the breast cancer patients with Luminal-A only with grade-1 and -2 cancers, for Kaplan–Meir plotter [(b) p < 0.05]. 
Abbreviations: HR, hazard ratio; SP-D, surfactant protein D.
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the analysis based on different tumor settings. The bioinformatics 
analysis highlighted a favorable prognostic effect of SP-D mRNA 
expression in the lung cancer, both in adenocarcinoma and 
squamous cell carcinoma; on the contrary, an unfavorable prog-
nostic effect in gastric, ovarian, and breast cancer was revealed. In 
particular, SP-D mRNA expression showed a negative correlation 
with the intestinal-type gastric adenocarcinomas, grade-1 and 
grade-2 breast cancers and with stage-1 and -2 ovarian cancers. 
No significant correlation was showed within stage-3 and -4 in 
breast and ovarian cancers.
Sin et  al. (28) have suggested that low SP-D levels may be 
correlated with the development of lung cancer. They observed 
a reduction of the concentration of SP-D in the bronchoalveolar 
lavage fluid of heavy smokers that was linked to bronchial dyspla-
sia. More recently, Hasegawa et al. (19) noted the presence of SP-D 
in lung cancer, and demonstrated that SP-D was able to interfere, 
via its CRD region, with the interaction between EGF and EGF 
receptor (EGFR), a tyrosine kinase receptor of the ErbB family, 
causing downregulation of the EGF induced signaling (19). EGFR 
is commonly altered in epithelial tumors and its dysregulation 
leads to cell proliferation, angiogenesis, invasion, and metastasis 
(29). Furthermore, it has been recently demonstrated that SP-D 
is also able to interact with the mutant form of EGFR, inhibiting 
its ligand-independent dimerization (29). In addition, Kaur et al. 
FigUre 5 | Representative immunohistochemical microphotographs of surfactant protein D (SP-D) expression in the healthy gastric mucosa (a), and  
ductal mammary epithelium (b) and their malignant histotypes intestinal-type gastric adenocarcinoma (c) and invasive ductal breast carcinoma, Luminal-A  
(D). A decreased expression of SP-D in the intestinal-type gastric adenocarcinoma and invasive ductal breast carcinoma, Luminal-A respect to their normal 
counterparts can be observed. Polymer detection system with AEC (red) chromogen; scale bars, 50 µm.
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have reported the ability of a recombinant truncated form of 
human SP-D to induce apoptosis via TNF-α/Fas-mediated path-
way in human pancreatic adenocarcinoma using Panc-1 (p53mt), 
MiaPaCa-2 (p53mt), and Capan-2 (p53wt) cell lines. Treatment 
of these cell lines with a recombinant form of truncated human 
SP-D (made up of homotrimeric neck and C-type lectin domains) 
for 24 h caused growth arrest in G1 cell cycle phase and triggered 
transcriptional upregulation of pro-apoptotic factors such as 
TNF-α and NF-κB. Translocation of NF-κB from the cytoplasm 
into the nucleus of pancreatic cancer cell lines was observed fol-
lowing treatment with SP-D. SP-D treatment caused upregulation 
of pro-apoptotic marker Fas, which then triggered cleavage of 
caspase 8 and 3. This study raises the possibility of using recom-
binant SP-D as a therapeutic molecule against pancreatic cancer 
irrespective of their p53 phenotype (20).
The EGFR is commonly overexpressed in non-small cell lung 
cancer (in 89% squamous cell carcinoma; 41% adenocarcinomas) 
(30), and therefore, it is considered a potential target for cancer 
therapy (30). The presence of SP-D in these cancers could exert 
a protective effect via downregulation of the EGFR pathway. It 
has also been shown that serum level of SP-D reflects its levels 
in the lung and that higher amount of SP-D in the serum cor-
related with better overall survival in patients with EGFR mutant 
adenocarcinoma undergoing treatment with gefitinib, a tyrosine 
kinase inhibitor (29).
Our study appears to highlight a more favorable prognosis for 
adenocarcinoma with respect to squamous cell carcinoma. A pos-
sible explanation of this observation may be that adenocarcinoma 
originates from peripheral airways progenitor cells that are able 
to produce SP-D. Moreover, more SP-D production may be 
indicative of a more differentiated cancer.
SFTPD, together with a number of genes selectively expressed 
in the respiratory epithelial cells, is under the control of the thyroid 
transcription factor 1 (TTF-1) (31, 32). A recent meta-analysis 
showing that TTF-1 overexpression is related to a favorable prog-
nosis for non-small cell lung carcinoma patients (33), appears to 
strengthen the results being reported here.
Although the overexpression of the EGFR gene has also been 
reported in a variety of other cancers including those of head and 
neck, ovary, cervix, bladder, esophagus, stomach, brain, breast, 
endometrium, and colon (24), the above-mentioned mechanisms 
cannot explain the opposite results obtained via the bioinformat-
ics analysis of Kaplan–Mayer dataset for gastric, ovarian, and 
breast carcinomas, where SP-D showed an unfavorable prognostic 
effect. We think that the unfavorable prognostic effect of SP-D in 
other tumor settings can be due to its direct or indirect action on 
the immune population present in the tumor microenvironment 
(15). The following mechanisms can explain the role of SP-D 
in determining a tumor microenvironment favorable to tumor 
progression. For example, the protective effect of SP-D against 
breast cancer cells can be negated by the presence of hyaluronic 
acid, which is abundantly present in the microenvironment of 
a number of solid tumors (34) (Murugaiah, Bulla, and Kishore, 
unpublished data).
SP-D is able to reduce the expression of CD11c (15). CD11c is 
predominantly expressed on dendritic cells, but also on effector 
FigUre 6 | Pathological significance of SP-D expression in ovarian cancer. Yoshihara’s and TCGA’s datasets explored SP-D mRNA expression in ovarian cancer.  
A higher SP-D mRNA expression was detectable in serous cystadenocarcinoma than that in normal ovary [(a) p < 0.05]. According to the data from Kaplan–Meir 
plotter, SP-D mRNA expression showed a negative relationship both overall or progression-free survival rates of patients with serous cystadenocarcinoma, if 
stratified by stage-1 and -2 [(b) p < 0.05]. Abbreviations: HR, hazard ratio; SP-D, surfactant protein D.
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cells in the local tumor microenvironment, such as some mac-
rophages, natural killer (NK), and activated T cells (25). It has 
been shown that low CD11c expression indicates unfavorable 
prognosis in patients with gastric cancer (35).
SP-D can promote production of TNF-α and IFN-γ (16, 
18, 36). The anti-tumor effects of Th1  cells may reflect their 
known role in enhancing CD8+ T cell responses and activating 
macrophages, through the secretion of TNF-α and IFN-γ. IFN-γ 
can increase tumor cell class I MHC expression and sensitivity to 
lysis by NK cells and cytotoxic T lymphocytes (CTLs). Besides, 
antigen-presenting cells such as macrophages and dendritic cells 
can directly activate antigen-specific Th1 or CTLs, which can 
activate the anti-tumor immune response and are thus associated 
with favorable prognosis in a diverse range of cancers (37, 38).
It has been demonstrated that SP-D binds to lymphocytes 
and suppress T cell proliferation (14) via apoptosis induction in 
activated PBMCs. SP-D has been shown to enhance expression 
of CTLA-4, a negative regulator of T cell activation and prolifera-
tion (39). In addition, monocytes expressed CTLA-4, but only the 
lymphocytes treated with SP-D show a significant overexpression of 
CTLA-4 (15). There are strong experimental and clinical evidence 
to suggest that T cell responses to some tumors are inhibited by 
the involvement of CTLA-4, one of the best-defined inhibitory 
pathways in T  cells (40, 41). In fact, tumor-infiltrating T  cells 
often have a dysfunctional (exhausted) phenotype that is charac-
terized by impaired effector functions and increased expression 
of CTLA-4 and other inhibitory molecules (40, 41). Blockade of 
the CTLA-4 pathways is now being widely used in the clinic to 
reverse the dysfunctional phenotype of tumor-specific T  cells 
and enhance their ability to kill tumor cells (41). Thus, SP-D, 
by increasing the expression of CTLA-4, may contribute to the 
inhibition of the anti-tumor immune responses.
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SP-D is able to inhibit the IL-12p40 production by macrophages 
via the SIRPα/ROCK/ERK signaling pathway (12). IL-12p40 is a 
component of IL-12p70 and IL-23, and its regulation is important 
for both innate and adaptive immunity. IL-12p40 is a marker of 
M1-like macrophages and data indicate that IL-12p40 may be 
contributing to inducing Th 1 polarization (42, 43). Macrophages 
derived from IL-12p40-deficient mice have a bias toward M2-like 
polarization (42). The production of IL-12p40 by macrophages 
and dendritic cells is associated with the ability to migrate to the 
lymph node and initiate T cell responses (44). We think that SP-D 
repressing the expression of IL-12p40 in macrophages may main-
tain the steady M2-like polarization and inhibit Th1 polarization.
SP-D has also been shown to interact with the leukocyte-
associated Ig-like receptor-1 (LAIR-1) (45), known as CD305. 
This molecule is a transmembrane glycoprotein and is 
expressed on almost all immune cells as well as CD34+ hemat-
opoietic progenitor cells. SP-D acts as a ligand for the inhibi-
tory receptor LAIR-1, which inhibits the function of multiple 
types of immune cells (45), indicating that SP-D present in the 
tumor microenvironment may exert its immunomodulatory 
effect and inhibit the anti-tumor immune responses through 
LAIR-1 activation. Thus, the context of immune infiltration 
and composition of tumor microenvironment are likely to 
dictate the consequent effects of SP-D, and hence, tumor 
progression or resistance.
In summary, our in  silico analysis, if confirmed with a ret-
rospective study at the protein level, could highlight a possible 
role of SP-D as a novel marker for tumor prognosis in a range of 
cancers. The presence of SP-D could be associated with a favora-
ble prognosis in lung cancer where it has been demonstrated to 
downregulate the EGF signaling, and unfavorable prognosis in 
non-pulmonary sites such as gastric, breast, and ovarian cancers.
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FigUre 7 | Quantitative real-time PCR analysis of surfactant protein D (SP-D) performed on the normal ovarian epithelium and the epithelial ovarian tumor 
(a). Representative microphotographs showing an enrichment in SP-D positive cells in the serous cystadenocarcinoma (b) compared to the normal ovarian 
epithelium (c). Polymer detection system with AEC (red) chromogen; scale bars, 50 µm.
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FigUre s1 | Surfactant protein D (SP-D) expression in lung cancer. Garber’s 
dataset has explored SP-D mRNA expression in the lung cancer. A lower SP-D 
mRNA expression was detectable in large cell carcinoma, adenocarcinoma, 
squamous cell carcinoma, and small cell carcinoma than in normal lung tissue 
(p < 0.05).
FigUre s2 | Surfactant protein D (SP-D) expression in gastric cancer. DErrico’s 
dataset has revealed a lower SP-D mRNA expression in intestinal-type 
adenocarcinoma than in normal mucosa (p < 0.05).
FigUre s3 | Pathological significance of SP-D expression in breast cancer. 
Curtis’s dataset has revealed a lower SP-D mRNA expression in phyllodes tumor 
than in normal breast tissue [(a) p < 0.05]. There was a negative association 
between SP-D mRNA expression and a favorable prognosis in the breast cancer 
patients with Luminal-A with grade-1, for Kaplan–Meir plotter [(b) p < 0.05]. 
Abbreviations: HR, hazard ratio; SP-D, surfactant protein D.
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